Basit öğe kaydını göster

dc.contributor.authorEfe, Nihal
dc.contributor.authorAltas, Enver
dc.contributor.authorMazlumoğlu, Muhammet Recai
dc.contributor.authorAktan, Bülent
dc.contributor.authorÜçüncü, Harun
dc.contributor.authorEren, Suat
dc.contributor.authorÖner, Fatih
dc.date.accessioned2020-11-20T15:02:01Z
dc.date.available2020-11-20T15:02:01Z
dc.date.issued2016
dc.identifier.issn1049-2275
dc.identifier.issn1536-3732
dc.identifier.urihttps://doi.org/10.1097/SCS.0000000000002983
dc.identifier.urihttps://hdl.handle.net/20.500.12809/2342
dc.descriptionWOS: 000386352100100en_US
dc.descriptionPubMed ID: 27513783en_US
dc.description.abstractThough the lymphangioma is a benign neoplasm, it may make an invasion to vital structures by progressively growing. For lymphangioma, which progressed in such a way, surgical treatment has high morbidity and recurrence risk. On these cases, OK-432 is a frequently used sclerotherapy agent. The authors report the result they obtained by the use of single-dose OK-432 on an inoperable pediatric cervical macrocystic lymphangioma case and also their experiences.en_US
dc.item-language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.item-rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCervical Macrocystic Lymphangiomaen_US
dc.subjectOK-432en_US
dc.subjectSclerotherapyen_US
dc.titleExcellent Result With the Use of Single-Dose OK-432 in Cervical Macrocystic Lymphangiomaen_US
dc.item-typearticleen_US
dc.contributor.departmentMÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorÜçüncü, Harun
dc.identifier.volume27en_US
dc.identifier.issue7en_US
dc.identifier.startpage1802en_US
dc.identifier.endpage1803en_US
dc.relation.journalJournal of Craniofacial Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster